Matching articles for "trametinib"
Issue 1704 · June 10, 2024
Tovorafenib (Ojemda) for Pediatric Low-Grade Glioma (online only)

Tovorafenib ( Ojemda – Day One), a type II RAF kinase inhibitor, has received accelerated approval from the FDA for treatment of patients ≥6 months old with relapsed or refractory pediatric low-grade…

Med Lett Drugs Ther. 2024 Jun 10; 66(1704):e97-8 doi:10.58347/tml.2024.1704f
Tovorafenib ( Ojemda – Day One), a type II RAF kinase inhibitor, has received accelerated approval from the FDA for treatment of patients ≥6 months old with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or a BRAF V600 mutation. Tovorafenib is the first systemic treatment to be approved in the US for pediatric low-grade gliomas with BRAF fusions. Accelerated approval of tovorafenib was based on response rates and duration of response.
Issue 1701 · April 29, 2024
Lifileucel (Amtagvi): A Cellular Therapy for Melanoma (online only)

Lifileucel ( Amtagvi – Iovance), a tumor-derived autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic melanoma…

Med Lett Drugs Ther. 2024 Apr 29; 66(1701):e77-8 doi:10.58347/tml.2024.1701h
Lifileucel ( Amtagvi – Iovance), a tumor-derived autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic melanoma previously treated with a programmed death receptor-1 (PD-1) inhibitor, and if BRAF V600 mutation-positive, a BRAF inhibitor with or without a mitogen-activated kinase (MEK) inhibitor. It is the first cellular therapy to be approved for use in solid tumors. Accelerated approval of lifileucel was based on objective response rates.
Issue 1674 · April 17, 2023 Free
In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)

The oral kinase inhibitors dabrafenib ( Tafinlar – GSK) and trametinib ( Mekinist – Novartis) have been approved by the FDA for use together for a sixth indication: treatment of low-grade glioma (LGG) with…

Med Lett Drugs Ther. 2023 Apr 17; 65(1674):e75-6 doi:10.58347/tml.2023.1674i
The oral kinase inhibitors dabrafenib ( Tafinlar – GSK) and trametinib ( Mekinist – Novartis) have been approved by the FDA for use together for a sixth indication: treatment of low-grade glioma (LGG) with a BRAF V600E mutation in patients ≥1 years old who require systemic therapy. This combination is the first systemic therapy to be approved in the US for first-line treatment of LGG with a BRAF V600E mutation in pediatric patients. The FDA also approved new oral formulations of both drugs for patients who are unable to swallow dabrafenib capsules or trametinib tablets.
Issue 1669 · February 6, 2023 Free
In Brief: A New Indication for Dabrafenib (Tafinlar) and Trametinib (Mekinist) Combination Therapy (online only)

The oral kinase inhibitors dabrafenib ( Tafinlar – GSK) and trametinib ( Mekinist – Novartis) have received accelerated approval by the FDA for use together for a fifth indication: treatment of…

Med Lett Drugs Ther. 2023 Feb 6; 65(1669):e26-7 doi:10.58347/tml.2023.1669f
The oral kinase inhibitors dabrafenib ( Tafinlar – GSK) and trametinib ( Mekinist – Novartis) have received accelerated approval by the FDA for use together for a fifth indication: treatment of unresectable or metastatic solid tumors with a BRAF V600E mutation in patients ≥6 years old who have progressed following prior treatment and have no satisfactory alternative treatment options. The combination is not approved for treatment of colorectal cancer because of known intrinsic resistance to BRAF inhibition and dabrafenib is not approved for use in patients with wild-type BRAF melanoma, anaplastic thyroid cancer (ATC), or solid tumors.
Issue 1668 · January 23, 2023
Opdualag for Metastatic Melanoma (online only)

Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo) , a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3)…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):e19-20 doi:10.58347/tml.2023.1668g
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo) , a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA for treatment of unresectable or metastatic melanoma in patients ≥12 years old. Relatlimab, which is only available in combination with nivolumab, is the first LAG-3 blocking antibody to become available in the US. Immune checkpoint inhibitors, including the anti-CTLA-4 antibody ipilimumab (Yervoy) and the PD-1 inhibitors nivolumab and pembrolizumab (Keytruda) , have been available for several years for treatment of melanoma.
Issue 1491 · March 28, 2016
Cobimetinib (Cotellic) for Metastatic Melanoma

The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib ( Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib…

Med Lett Drugs Ther. 2016 Mar 28; 58(1491):43-4
The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib ( Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib (Zelboraf) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Issue 1470 · June 8, 2015
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC

The FDA has approved nivolumab ( Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with…

Med Lett Drugs Ther. 2015 Jun 8; 57(1470):85-7
The FDA has approved nivolumab ( Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (and a BRAF inhibitor in patients who are BRAF V600 mutation positive) and for treatment of metastatic squamous non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy. It is the second PD-1 inhibitor to be marketed in the US after pembrolizumab (Keytruda) , and the first to be approved for treatment of NSCLC.
Issue 1455 · November 10, 2014
Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)

The FDA has approved pembrolizumab ( Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following…

Med Lett Drugs Ther. 2014 Nov 10; 56(1455):e114-5
The FDA has approved pembrolizumab ( Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (Yervoy) and, if the patient is BRAF V600 mutation positive, a BRAF inhibitor. It is the fi rst PD-1 inhibitor to be marketed in the US. Nivolumab, another PD-1 inhibitor, is available in Japan. Pembrolizumab was previously known as lambrolizumab.
Issue 1422 · August 5, 2013
Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma

The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib ( Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib ( Mekinist –…

Med Lett Drugs Ther. 2013 Aug 5; 55(1422):62-3
The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib ( Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib ( Mekinist – GSK) for melanomas with either BRAF V600E or V600K mutations. Dabrafenib is not recommended for patients with wild-type BRAF (BRAF-negative) melanoma, and trametinib is not recommended for patients who have received prior BRAF-inhibitor therapy.